Cancer Of The Female Lower Genital Tract

This volume of the American Cancer Society Atlas of Clinical Oncology is intended to provide clinicians, students, and scientists with an integrated analysis and review of the biology, diagnostic evaluation, and treatment of cancers of the lower female genital tract. Recent changes in the accepted treatment for invasive cervical cancer, and in many aspects of the epidemiology, diagnosis, and evaluation of these cancers, make this discussion particularly timely.

This full-colour atlas offers a comprehensive visual guide to diagnosis, management and post-treatment care for all stages of gynaecologic cancer.

Almost all known tumors and tumor-like conditions of the fe- male lower genital tract are classified in this complete mo- nograph on the subject. Clinical features, treatment and prognosis ar included, making this book a practical refe- rence for the busy clinician.

The guide to effective practice management of precancerous lesions in cervix and lower genital tract. This third edition contains in-depth examination of the different modalities that contribute to the safe and scientific management of precancerous lesions in the female genital tract. One of the most important is colposcopy which provides an accurate and effective route to their identification. Professor Albert Singer is internationally recognized as a master of colposcopy. His training courses throughout the world are in high demand. In this edition, he has teamed with fellow expert Ashfaq Khan to present a very accessible, authoritative and highly illustrated guide to the power of colposcopy. Practical pictorial guidance to recognizing potentially cancerous abnormalities in the cervix, vagina, and vulva is framed by internationally agreed disease classifications. Consensus guidelines from the US and Europe provide a rigorous platform for management advice. The latest information on HPV, the role of biomarkers, and new methods in diagnosis and treatment are all featured. Cervical and Lower Genital Tract Precancer is the ideal companion for anyone wishing to incorporate safe and scientific methods of diagnosis and treatment into their clinical practice.

****When not purchasing directly from the official sales agents of the WHO, especially at online bookshops, please note that there have been issues with counterfeited copies. Buy only from known sellers and if there are quality issues, please contact the seller for a refund.***** Female Genital Tumours is the fourth volume in the 5th edition of the WHO series on the classification of human tumours. This series (also known as the WHO Blue Books) is regarded as the gold standard for the diagnosis of tumours and comprises a unique synthesis of histopathological diagnosis with digital and molecular pathology. These authoritative and concise reference books provide indispensable international standards for anyone involved in the care of patients with cancer or in cancer research, underpinning individual patient treatment as well as research into all aspects of cancer causation, prevention, therapy, and education. What's new in this edition? The 5th edition, guided by the WHO Classification of Tumours Editorial Board, will establish a single coherent cancer classification presented across a collection of individual volumes organized on the basis of anatomical site (digestive system, breast, soft tissue and bone, etc.) and structured in a systematic manner, with each tumour type listed within a taxonomic classification: site, category, family (class), type, and subtype. In each volume, the entities are now listed from benign to malignant and are described under an updated set of headings, including histopathology, diagnostic molecular pathology, staging, and easy-to-read essential and desirable diagnostic criteria. Who should read this book? - Pathologists - Oncologists - Cancer researchers - Surgeons - Epidemiologists - Cancer registrars This volume - Prepared by 191 authors and editors - Contributors from around the world - More than 850 high-quality images - More than 3100 references

The new Second Edition of Lower Genital Tract Precancer has been extensively revised and expanded to provide a definitive and contemporary reference on this subject. Providing a comprehensive examination of the applications and benefits of modern diagnostic and therapeutic practices in managing lesions of the female lower genital tract, the book is presented in a clear, easy-to-read style and is extensively illustrated. The text covers investigative procedures and techniques, reviews the normal and abnormal cervix and fully appraises the diagnosis and management of both benign and malignant lesions. Vaginal, vulvular and perianal premalignant diseases are discused, and a separate section is devoted to those conditions which mimic, and can thus be confused with, precancer. A new section on AIDS has been included and an entire chapter on pathology is also incorporated.

This book aims to promote awareness of and highlight the screening modalities and various treatment options available for the management of cervical pre-invasive lesions. Cervical cancer is the leading cause of malignancy among women worldwide, and deaths due to cervical cancer represent a global health problem. Yet the risk of cervical malignancy can be decreased substantially if the premalignant conditions of the cervix are recognized and treated in a timely manner. Colposcopy is the gold standard for the diagnosis of cervical dysplasia. Accordingly, the book details the fundamentals of colposcopy and colposcopic assessment of the normal and abnormal cervix. With preventive oncology taking front stage, colposcopy has become one of the most important diagnostic tools available. With chapters contributed by respected experts in this field, the book offers vital insights into colposcopy and an essential guide to comprehensive strategies for the early detection of cervical cancer. The main text is complemented by ample illustrations for clarity and a better understanding of the subject. Case discussions on various clinical scenarios will further ensure good clinical practices, which will in turn translate into reduced risk of cervical cancer.